Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Looking at Evolus' DWP-450 (PrabotulinumtoxinA) purified botulinum toxin in treating glabellar (frown) lines

Ticker(s): EOLS, RVNC, AGN

Who's the expert?

Name: Dr Katie Beleznay - MD

Institution: UBC and Carruthers & Humphrey Cosmetic Medicine

  • Clinical Instructor with the University of British Columbia Department of Dermatology; board certified dermatologist in both Canada and the United States and is fellowship trained in laser and cosmetic dermatology.
  • Treats 5-15 patients a day 4 days a week with Botox.
  • Sub-investigator for the BELMONT Phase 2 trial of DaxibotulinumtoxinA Injectable (RT002).

Interview Questions
Q1.

Please describe your clinical practice; roughly how many patients do you currently treat with injectables for glabellar lines?

Added By: c_admin
Q2.

What are your initial thoughts on DWP-450 (PrabotulinumtoxinA)? If approved how likely would you be to switch patients off Botox?

Added By: c_admin
Q3.

On a scale from 1-10, 10 being extremely excited, where would you rate your level of excitement for this drug?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.